Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Exploring the Link Between Cancer Genetics and PPSP

2 juillet 2019 mis à jour par: Institute of Cancer Research, United Kingdom

Exploring the Link Between Cancer Genetics and Persistent Post-surgical Pain (PPSP) Following Breast Cancer Treatment

Pain is common in cancer, affecting between 40 and 60% of patients depending on tumour type and stage of disease, and represents a major area of unmet need in cancer survivors. Despite advances in treatment, there has been no significant reduction in those who experience pain. Breast cancer is common. It represents 10% of newly diagnosed cancers globally and is often associated with pain.

Exact physiological mechanisms for cancer pain are not yet fully established. There is a complex relationship between a malignant lesion and its micro-environment; a tumour does not exist in isolation but has a dynamic relationship with host cells. There is a growing interest in delineating the relationship between tumour manifestations and pain.

By retrospectively identifying individuals who have been referred to specialist pain clinics at a cancer centre and matching them to controls, the investigators can identify two groups of patients (those who experienced significant problems with pain and those who did not). Accessing paraffin-embedded tissue samples from those that have had surgical resections, will allow the investigators to compare tissue samples, in particular the metabolic and genetic differences, between the two groups.

No new tissue samples will be required for this study.

Pain is a major area of unmet need in cancer survivors. The investigators propose that this project would provide valuable knowledge and pilot data regarding the link between pain and tumour genetics. It has the potential to identify tumour genes or mutations that are associated with greater incidences of pain and ultimately potentially guide targeted interventions to help reduce the frequency and impact of pain on patients living with and beyond cancer.

Aperçu de l'étude

Description détaillée

This study will be a retrospective, case-control study. There will be two groups of patients identified retrospectively:

The first group will be patients who have been referred to the pain management team for persistent-post surgical pain following breast cancer treatment.

The second group, will consist of patients who have been matched for age, procedure and time-lapsed since operation. These patients will not have persistent post-surgical pain.

Archived paraffin-embedded tissue samples, that have previously been taken from these patients, will be required. Samples accessed will be from patients who have previously provided consent for their samples to be used for research purposes. Once appropriate samples have been identified by the tissue banks, all data will be pseudonymised. This will include details that patients have consented to providing for research purposes via the Pain Management Database, which has Trust (CCR 442) and Research Ethics Committee (REC 16/LO/1989) approval.

Laboratory studies will then be conducted to A) investigate the underlying variations of the PIK3CA gene of tumours within the two cohorts of patients, B) investigate other genetic variations between these two groups and C) establish the key genetic and signalling pathway alterations between these two groups.

The methods by which these investigations will be conducted will be by performing PIK3CA genomics, genetic profiling, next generation sequencing and finally immunohistochemistry for activation of signalling pathways.

This study will analyse archived paraffin embedded tissue samples in a laboratory only.

The anticipated time-scale for this project would be approximately one year.

Type d'étude

Observationnel

Inscription (Anticipé)

104

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

Although two groups of patients will be identified retrospectively:

  1. The first group will be patients who have been referred to the pain management team for persistent-post surgical pain following breast cancer treatment.
  2. The second group, will consist of patients who have been matched for age, procedure and time-lapsed since operation. These patients will not have persistent post-surgical pain.

Ultimately, archived paraffin-embedded tissue samples, that have previously been taken from these patients, will be requested. Samples accessed will be from patients who have previously provided consent for their samples to be used for research purposes.

La description

Inclusion Criteria:

  • Patients receiving treatment at the Royal Marsden Hospital.
  • Patients with a diagnosis of primary breast cancer.
  • Patients who have had surgical resection of their breast tumour.
  • Paraffin-embedded tissue samples available from Royal Marsden Tissue Banks.

Exclusion Criteria:

  • Under 18 years of age.
  • Lack of adequate tissue sample available from the Tissue Bank.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Cohortes et interventions

Groupe / Cohorte
Patients with pain

This will be the group of patients in whom pain is a significant enough problem, that they have been referred to the specialist Pain Management Team. These patients will be identified retrospectively.

Patients seen in Pain Management Clinics between 1st of January 2016 and 31st of December 2018, who have consented to be included in the Pain Management database and have a clinician specified pain diagnosis of pain persistent post-surgical pain following breast cancer treatment will be identified. If these patients have an unclear pain diagnosis, they will not be included.

Patients without pain

This will be the group of patients in whom pain is deemed not to be a significant problem.

Once again, these patients will be identified retrospectively. Appropriately matched patients to the 52 patients in the "patients with pain" will be identified using records of hospital operating lists by the peri-operative medicine team.

Patients will be matched based upon the following details:

  • Age (within 5 years of matched case)
  • Surgical procedure (matched for the following elements:

    • Surgery to breast tissue (biopsy, lumpectomy, wide-local excision or mastectomy)
    • +/- Sentinal lymph node biopsy or axillary dissection
    • +/- Reconstruction
  • Surgical procedure within 3-months of matched case.

Provided these individuals have not had an appointment with or referral to the Pain Management Team, they will be included in the matched controls.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
The difference in the proportion of mutations of the PIK3CA gene.
Délai: Within 6-8months
PIK3CA genomics will result in a binary measure (either wild-type or mutant). The difference in proportion of the PIK3CA gene mutation in those with persistent post-surgical pain compared with those without persistent post-surgical pain will be the primary outcome measure.
Within 6-8months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Proportion of individual gene mutations in pain group compared with the no pain group.
Délai: Within 6-8months
DNA analysis will determine the presence or absence of other gene mutations (binary outcome).
Within 6-8months
Difference in mean gene expression in those with pain compared with those without pain.
Délai: Within 6-8months
Exploring the difference in gene expression between the two groups.
Within 6-8months
Proportion of individual DNA copy number changes (either amplification/gain or loss) in those with pain compared with those without pain.
Délai: Within 6-8months
DNA copy number can either be unchanged or changed. Changes are described as either 'amplification/gain' or 'loss'. Data will be analysed as binary data (either no change or change).
Within 6-8months
Frequency of changes to DNA copy number (either amplification/gain or loss) in those with pain compared with those without pain.
Délai: Within 6-8months
DNA copy number can either be unchanged or changed. Changes are described as either 'amplification/gain' or 'loss'. Data will be analysed as binary data (either no change or change).
Within 6-8months
Difference in median of magnitude of activation status of signalling pathways between those with pain and those without pain.
Délai: Within 6-8months
Comparison the activation status of signalling pathways between the two groups. The magnitude of activation status will be reported as a percentage.
Within 6-8months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Matt Brown, MBBS, Royal Marsden NHS Foundation Trust

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Anticipé)

1 juillet 2019

Achèvement primaire (Anticipé)

1 décembre 2019

Achèvement de l'étude (Anticipé)

1 décembre 2019

Dates d'inscription aux études

Première soumission

21 juin 2019

Première soumission répondant aux critères de contrôle qualité

2 juillet 2019

Première publication (Réel)

5 juillet 2019

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

5 juillet 2019

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 juillet 2019

Dernière vérification

1 juillet 2019

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • CCR 5006

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner